Boehringer Ingelheim

Boehringer Ingelheim is a leading research-driven biopharmaceutical company, creating value through innovation in areas of high unmet medical need.

One of the world’s largest manufacturers of biopharmaceuticals, Boehringer Ingelheim is an industry pioneer and has produced more than 40 commercial biopharmaceuticals. Our contract manufacturing business, Boehringer Ingelheim BioXcellence™ reliably supplies innovative therapies that transform lives, today and for generations to come and creates solutions with its partners to improve patient health through its production network spanning the globe, from Biberach, Germany to Vienna, Austria, Shanghai, China and Boehringer Ingelheim Fremont Inc., in California, United States.

A mammalian cell culture center in the San Francisco Bay Area, Boehringer Ingelheim Fremont, Inc., has more than 600 scientists and specialists committed to research, development, and manufacturing to deliver high quality medicines for patients. Our modern facility offers high flexibility with stainless steel and single-use bioreactors for fed-batch and process intensification technology manufacturing. With the complete range of services, from cell line and strain development, including high expression systems, through process development and large-scale manufacturing, to Fill & Finish we help our customers to turn innovative biologic ideas into commercial reality.

6701 Kaiser Drive
Fremont, CA 94555 US

Visit website

NEWS

Lagging behind competitors, businessmen stand behind competitors on the race track

Obesity

ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction

While survodutide’s 16.6% overall weight loss was underwhelming, Boehringer Ingelheim and Zealand Pharma’s drug achieved “impressive” fat loss, according to BMO Capital Markets.

June 8, 2026

2 min read

Tristan Manalac

Obesity

Lilly and Novo face off at ADA 2026 as others seek to compete in obesity

The American Diabetes Association’s annual congress will feature a superstar lineup, including weight loss giants Eli Lilly and Novo Nordisk. But several scrappy biotechs will also present obesity candidates with the potential to match—if not outperform—their deep-pocketed competitors.

June 5, 2026

8 min read

Tristan Manalac

USA, EU and Greenland on the map of North Atlantic Ocean in soft grunge and vintage style, like old paper with watercolor painting.

Manufacturing

Lilly and Boehringer roll back billions in German investments over health budget cuts

With Germany moving to curb healthcare spending, Eli Lilly and Boehringer Ingelheim have rethought plans to invest in facilities, including a manufacturing plant for GLP-1 drugs.

June 4, 2026

2 min read

Nick Paul Taylor

Strategy for company development concept. Employees conduct comparative analysis to improve their work. Competitiveness of business. Cartoon flat vector illustration isolated on blue background

Obesity

Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3

Topline Phase 3 results of survodutide—licensed to Boehringer Ingelheim from Zealand Pharma—are more comparable to Novo Nordisk’s Wegovy than to Eli Lilly’s Zepbound, William Blair analysts said on Tuesday.

April 28, 2026

2 min read

Heather McKenzie

Set of crumpled lumps of different paper isolated on yellow background. Gritty dusty dotted effect, vector elements with jagged edges, old notebook sheets.

MASH

Boehringer Ingelheim Axes MASH Pact With OSE After Disappointing Mid-Stage Data

OSE Immunotherapeutics has kicked off a strategic realignment initiative that involves deprioritizing the AbbVie-partnered OSE-230 and focusing its resources on the late-stage development of its ulcerative colitis candidate lusvertikimab.

March 3, 2026

2 min read

Tristan Manalac

Female hand showing thumbs up gesture on blue background, art collage. Positive hand sign. Fashion collage in the style of Thumbs up magazine. Contemporary art. Modern design.

Approvals

Boehringer Wins Speedy Lung Cancer Approval Under Commissioner’s Priority Program

Hernexeos is the second drug to secure an FDA approval under the agency’s priority voucher scheme, following in the footsteps of USAntibiotics’ Augmentin XR, which was granted the ticket in December 2025.

February 27, 2026

2 min read

Tristan Manalac

Control, Complex work, Businessman balancing on a ball

Deals

Boehringer Seeks To Rebalance Immunity With Sitryx Collab Potentially Worth $500M+

While Boehringer Ingelheim hasn’t yet revealed what diseases it will go after, Sitryx’s oral drug candidate could potentially be disease-modifying for a variety of autoimmune and inflammatory conditions.

February 26, 2026

1 min read

Tristan Manalac

Pictured: Boehringer Ingelheim's office in California

Inflammatory bowel disease

Boehringer Commits up to $1.26B in IBD Pact With China’s Simcere

The cornerstone of the deal is SIM0709, which Simcere designed to target both TL1A and IL-23, crucial players in facilitating inflammation. Boehringer Ingelheim will advance the asset for inflammatory bowel diseases.

January 27, 2026

2 min read

Tristan Manalac

Trendy halftone collage. A hand holds a ringing alarm clock. Time, hurry up. Vector business concepts for graphic and web design, marketing and print materials, social media. Vector illustration

FDA

FDA Delays Decision for Lilly’s Obesity Pill Orforglipron, Other Priority Voucher Awardees: Report

Target action dates for drugs sponsored by Sanofi, Boehringer Ingelheim and Disc Medicine have also been pushed back despite assurances of swift reviews under the FDA’s new Commissioner’s National Priority Voucher program.

January 15, 2026

2 min read

Tristan Manalac

JOBS